Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

ProstaGene

ProstaGene
2010 FOUNDED
M&A STATUS
M&A LATEST DEAL TYPE
$27M LATEST DEAL AMOUNT
Description

Developer of a diagnostic test designed to distinguish benign from malignant prostate cancer. The company's prognostic test defines a group of patients with poor outcome based on a signature of gene expression in the patients prostate tumor and it also offers a platform for preclinical testing of therapies for metastatic prostate cancer, enabling patients to early detect and cure cancers.

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly Angel backed
Primary Industry
Other Healthcare Technology Systems
Other Industries
Biotechnology
Social/Platform Software
Parent Company
Primary Office
  • 100 Lancaster Avenue
  • Room 133
  • Wynnewood, PA 19096
  • United States

+1 (267) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore ProstaGene’s full profile, request a free trial.

ProstaGene Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 16-Nov-2018 $27M 00.00 000.00 Completed Generating Revenue
2. Angel (individual) 17-Apr-2016 00000 00.00 Completed Generating Revenue
1. Angel (individual) 19-May-2015 $1M $1M Completed Generating Revenue
To view this company’s complete deal history including valuation and funding, request access »

ProstaGene Competitors (4)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NantCell Angel-Backed Culver City, CA 00000 000000000000 00000
0000 00000000000 Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
000000000 Venture Capital-Backed Rockville, MD 000.00 0000000000 0 000.00
000000000 00000000 Venture Capital-Backed San Carlos, CA 000.00 0000000000 0 000.00
To view this company’s complete list of competitors, request access »

ProstaGene Former Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Rebecca Matthias Angel (individual) Minority 000 0000 000000 0
Thomas Jefferson University University Minority 000 0000 000000 0

ProstaGene Executive Team (2)

Name Title Board
Seat
Contact
Info
Richard Pestell Ph.D Founder, Board Member & Chief Executive Officer

1 Former Executive

You’re viewing 1 of 2 executives. Get the full list »

ProstaGene Board Members (1)

Name Representing Role Since Contact
Info
Daniel Matthias ProstaGene Advisor,Board Member & Founding Investor 000 0000